AKT1 and breast carcinoma: Alpelisib is an α-specific class I PI3K inhibitor that inhibits the phosphorylation of downstream PI3K target proteins, including AKT, and it also inhibits the growth of PIK3CA mutant breast cancer cell lines in vitro and in vivo.